## Data Sharing Statement

<table>
<thead>
<tr>
<th>Item</th>
<th>Question</th>
<th>Authors’ Response (place “-” if not applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Would you like to share data collected for your study to others?</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>If not, would you like to share the reason for your decision?</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>What data in particular will be shared?</td>
<td>The data about survival analysis (by both Kaplan-Meier and COX analysis) in different groups in particular will be shared.</td>
</tr>
<tr>
<td>4</td>
<td>Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.</td>
<td>Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.</td>
</tr>
<tr>
<td>5</td>
<td>When will data availability begin?</td>
<td>From the publication date.</td>
</tr>
<tr>
<td>6</td>
<td>When will data availability end?</td>
<td>Two years within the publication date, since the technique or survival date may be updated over time</td>
</tr>
<tr>
<td>7</td>
<td>To whom will you share the data?</td>
<td>Cardiologists and radiologists who are interested in studies of LVNC.</td>
</tr>
<tr>
<td>8</td>
<td>For what type of analysis or purpose?</td>
<td>For analysis to investigate CMR characteristics and clinical consequences in patients with LVNC</td>
</tr>
<tr>
<td>9</td>
<td>How or where can the data/documents be obtained?</td>
<td>Emails could be sent to the address below to obtain the shared data: <a href="mailto:gykpanda@163.com">gykpanda@163.com</a></td>
</tr>
<tr>
<td>10</td>
<td>Any other restrictions?</td>
<td>We may balance the potential benefits and risks for each request and then provide the data that could be shared.</td>
</tr>
</tbody>
</table>